These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37569390)

  • 1. Investigating the Efficacy of
    Egea MB; Oliveira Filho JG; Lemes AC
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569390
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Briand F; Sulpice T; Giammarinaro P; Roux X
    Benef Microbes; 2019 May; 10(5):555-567. PubMed ID: 31090460
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Albuquerque RCMF; Brandão ABP; De Abreu ICME; Ferreira FG; Santos LB; Moreira LN; Taddei CR; Aimbire F; Cunha TS
    Benef Microbes; 2019 Dec; 10(8):901-912. PubMed ID: 31965836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
    Cui B; Lin L; Wang B; Liu W; Sun C
    Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition.
    Rodríguez-Nogales A; Algieri F; Garrido-Mesa J; Vezza T; Utrilla MP; Chueca N; García F; Rodríguez-Cabezas ME; Gálvez J
    J Nutr Biochem; 2018 Nov; 61():129-139. PubMed ID: 30236870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity of
    Czerucka D; Rampal P
    World J Gastroenterol; 2019 May; 25(18):2188-2203. PubMed ID: 31143070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
    Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
    mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-hypercholesterolemic effect of Saccharomyces boulardii in the hamster.
    Girard P; Pansart Y; Verleye M
    Pharmacology; 2014; 94(5-6):239-44. PubMed ID: 25427779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.
    Fu J; Liu J; Wen X; Zhang G; Cai J; Qiao Z; An Z; Zheng J; Li L
    Probiotics Antimicrob Proteins; 2023 Aug; 15(4):967-982. PubMed ID: 35608794
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yang Z; Wu Y; Liu X; Zhang M; Peng J; Wei H
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
    Wombwell E; Bransteitter B; Gillen LR
    Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive Effect of
    Babaei F; Mirzababaei M; Dargahi L; Shahsavari Z; Nassiri-Asl M; Karima S
    ACS Chem Neurosci; 2022 Nov; 13(22):3180-3187. PubMed ID: 36318666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Saccharomyces boulardii as a treatment option in IBD.
    Sivananthan K; Petersen AM
    Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Li B; Zhang H; Shi L; Li R; Luo Y; Deng Y; Li S; Li R; Liu Z
    Food Funct; 2022 Jan; 13(1):102-112. PubMed ID: 34878454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saccharomyces boulardii as therapeutic alternative in experimental giardiasis.
    Ribeiro MRS; Oliveira DR; Caliari MV; Cara Machado DC; Andrade MER; Cardoso VN; Dos Santos Martins F; Nicoli JR; Gomes MA
    J Appl Microbiol; 2021 Jul; 131(1):460-469. PubMed ID: 33289232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of broad-spectrum antibiotics on the colonisation of probiotic yeast Saccharomyces boulardii in the murine gastrointestinal tract.
    Hedin KA; Rees VE; Zhang H; Kruse V; Vazquez-Uribe R; Sommer MOA
    Sci Rep; 2022 May; 12(1):8862. PubMed ID: 35614092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
    Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
    Gut Microbes; 2017 Jan; 8(1):17-32. PubMed ID: 27973989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
    Sen S; Mansell TJ
    Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study.
    Ryan JJ; Hanes DA; Schafer MB; Mikolai J; Zwickey H
    J Altern Complement Med; 2015 May; 21(5):288-93. PubMed ID: 25893960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-promoting properties of
    Ansari F; Alian Samakkhah S; Bahadori A; Jafari SM; Ziaee M; Khodayari MT; Pourjafar H
    Crit Rev Food Sci Nutr; 2023; 63(4):457-485. PubMed ID: 34254862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.